中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝移植术后早期并发症的危险因素分析

解恩博 轩凤慧 孙晓东 孙大伟 吕国悦

引用本文:
Citation:

肝移植术后早期并发症的危险因素分析

DOI: 10.3969/j.issn.1001-5256.2018.06.030
详细信息
  • 中图分类号: R657.3

An analysis of risk factors for early complications after liver transplantation

  • 摘要:

    目的研究影响肝移植术后早期并发症的相关危险因素,以期改善患者预后。方法收集2011年9月-2017年4月于吉林大学白求恩第一医院肝移植中心接受原位肝移植术的147例肝移植患者的临床资料。根据早期并发症的有无分为无并发症组(n=11)和并发症组(n=136)。收集其可能发生术后早期并发症的相关因素,包括供体因素(年龄、供受体血型是否相符),受体因素[包括性别、年龄、原发病、MELD评分、AST、ALT、Alb、PLT、Hb、纤维蛋白原、TBil、肌酐、PLT/Alb比值(PAR)、中性粒细胞/淋巴细胞比值(NLR)],术中因素(包括冷缺血时间、热缺血时间、术中出血量、无肝期时间),术后因素(包括术后即时、12 h、24 h、48 h、72 h AST和ALT)。符合正态分布的计量资料2组间比较采用t检验;不符合正态分布的计量资料2组间比较采用Mann-Whitney U检验;多因素分析采用向后LR法logistic回归分析。结果单因素分析显示,MELD评分(t=-3.86,P=0.002)、Alb(t=2.19,P=0.049)、PLT(Z=467.00,P=0.039)、PAR(Z=5...

     

  • [1]SHI YH, TIAN MX, FAN J.Recommendations for EASL clinical practice guidelines:liver transplantation (2015) [J].J Clin Hepatol, 2016, 31 (3) :429-431. (in Chinese) 史颖弘, 田孟鑫, 樊嘉.《欧洲肝病学会肝移植临床实践指南 (2015年) 》推荐意见[J].临床肝胆病杂志, 2016, 31 (3) :429-431.
    [2]AZEVEDO LD, STUCCHI RS, ATAíDE EC.Assessment of causes of early death after twenty years of liver transplantation.[J].Transplant Proc, 2013, 45 (3) :1116-1118.
    [3]DAI CL, YIN YE, LI H, et al.Significance of various detection methods in diagnosis of cytomegalovirus infection[J].Chin J Lab Diag, 2010, 14 (12) :2058-2059. (in Chinese) 戴春来, 尹艳娥, 李恒, 等.各种检测方法在巨细胞病毒感染诊断中的意义[J].中国实验诊断学, 2010, 14 (12) :2058-2059.
    [4]CHEN XB, XU MQ.Primary graft dysfunction after liver transplantation[J].Hepatobiliary Pancreat Dis Int, 2014, 13 (2) :125-137.
    [5]European Association for the Study of the Liver.EASL clinical practice guidelines:Liver transplantation[J].J Hepatol, 2016, 64 (2) :433-485.
    [6]KOCHHAR G, PARUNGAO JM, HANOUNEH IA, et al.Biliary complications following liver transplantation[J].World J Gastroenterol, 2013, 19 (19) :2841-2846.
    [7] WANG JY, LIAO EY, HUANG CX, et al.Internal medicine[M].Beijing:People's Medical Publishing House, 2013:662. (in Chinese) 王吉耀, 廖二元, 黄从新, 等.内科学[M].北京:人民卫生出版社, 2013:662.
    [8]ZHOU L, PAN LC, SHI XJ, et al.Research advances in multicenter study on the role of the Model for End-Stage Liver Disease evaluation system in the selection of liver transplantation recipients[J].Organ Transplant, 2017, 8 (2) :174-178. (in Chinese) 周林, 潘立超, 史宪杰, 等.MELD评价体系对肝移植受者选择的多中心临床研究进展[J].器官移植, 2017, 8 (2) :174-178.
    [9]SABATE A, DALMAU A.Fibrinogen:a clinical update on liver transplantation[J].Transplant Proc, 2015, 47 (10) :2925-2928.
    [10]PORTE RJ, BLAUW E, KNOT EA, et al.Role of the donor liver in the origin of platelet disorders and hyperfibrinolysis in liver transplantation[J].J Hepatol, 1994, 21 (4) :592-600.
    [11]JALAN R, SCHNURR K, MOOKERJEE RP, et al.Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality[J].Hepatology, 2009, 50 (2) :555-564.
    [12]SHIRAI Y, SHIBA H, HARUKI K, et al.Preoperative platelet-to-albumin ratio predicts prognosis of patients with pancreatic ductal adenocarcinoma after pancreatic resection[J].Anticancer Res, 2017, 37 (2) :787-793.
    [13]POROWSKI D, WIRKOWSKA A, HRYNIEWIECKA E, et al.Liver failure impairs the intrahepatic elimination of interleukin-6, tumor necrosis factor-alpha, hepatocyte growth factor, and transforming growth factor-beta[J].Biomed Res Int, 2015, 2015:934065.
    [14]ALEXANDRAKIS MG, PASSAM FH, MOSCHANDREA IA, et al.Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis[J].Am J Clin Oncol, 2003, 26 (2) :135-140.
    [15]GASTACA M.Biliary complications after orthotopic liver transplantation:A review of incidence and risk factors[J].Transplant Proc, 2012, 44 (6) :1545-1549.
    [16]FREEMAN RB Jr, WIESNER RH, HARPER A, et al.The new liver allocation system:Moving toward evidence-based transplantation policy[J].Liver Transpl, 2002, 8 (9) :851-858.
    [17] WANG XM, PENG CH, YAN JQ, et al.Relationship between Meld score and the perioperative complications and mortality after orthtopic liver transplantation[J].Chin J Organ Transplant, 2007, 28 (2) :105-107. (in Chinese) 王小明, 彭承宏, 严佶祺, 等.Meld评分与肝移植围手术期并发症及死亡率的相关性[J].中华器官移植杂志, 2007, 28 (2) :105-107.
    [18]CHEN W, YI YX, ZHANG HB, et al.Evaluation effect of three scoring systems in the prediction of short-term outcomes following liver transplantation.[J].Chin J Hepatobiliary Surg, 2014, 20 (8) :557-561. (in Chinese) 陈威, 易永祥, 张海斌, 等.三种评分系统预测肝移植短期预后的效果评价[J].中华肝胆外科杂志, 2014, 20 (8) :557-561.
    [19]WIEDERKEHR JC, IGREJA MR, NOGARA MS, et al.Analysis of survival after primary liver transplantation:Multivariate analysis of 155 cases in a single center[J].Transplant Proc, 2010, 42 (2) :511-512.
    [20]SCHLEGEL A, LINECKER M, KRON P, et al.Risk assessment in high-and low-meld liver transplantation[J].Am J Transplant, 2017, 17 (4) :1050-1063.
    [21]HALLDORSON JB, RAYHILL S, BAKTHAVATSALAM R, et al.Serum alkaline phosphatase and bilirubin are early surrogate markers for ischemic cholangiopathy and graft failure in liver transplantation from donation after circulatory death[J].Transplant Proc, 2015, 47 (2) :465-468.
    [22]PLEVAK DJ, SOUTHORN PA, NARR BJ, et al.Intensive-care unit experience in the Mayo liver transplantation program:The first100 cases[J].Mayo Clinic Proceedings, 1989, 64 (4) :433-445.
    [23]SHAHEEN AA, MYERS RP.Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C related fibrosis a systematic review[J].Hepatology, 2007, 46 (3) :912.
    [24]EI SERAFY MA, KASSEM AM, OMAR H, et al.APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis:Systematic review and meta-analysis[J].Arab J Gastroenterol, 2017, 18 (2) :51-57.
    [25]JAIN A, REYES J, KASHYAP R, et al.Long-term survival after liver transplantation in 4, 000 consecutive patients at a single center[J].Ann Surg, 2000, 232 (4) :490-500.
    [26]DUFOUR DR, LOTT JA, NOLTE FS, et al.Diagnosis and monitoring of hepatic injury.II.Recommendations for use of laboratory tests in screening, diagnosis, and monitoring[J].Clin Chem, 2000, 46 (12) :2050-2068.
    [27]BAHDE R, SPIEGEL HU.Hepatic ischaemia-reperfusion injury from bench to bedside[J].Br J Surg, 2010, 97 (10) :1461-1475.
    [28]ARDITE E, RAMOS C, RIMOLA A, et al.Hepatocellular oxidative stress and initial graft injury in human liver transplantation[J].J Hepatol, 1999, 31 (5) :921-927.
    [29]GIANNINI EG, TESTA R, SAVARINO V.Liver enzyme alteration:A guide for clinicians[J].CMAJ, 2005, 172 (3) :367-379.
    [30]SEETO RK, FENN B, ROCKEY DC.Ischemic hepatitis:Clinical presentation and pathogenesis[J].Am J Med, 2000, 109 (2) :109-113.
    [31]DETRY O, DEROOVER A, MEURISSE N, et al.Donor age as a risk factor in donation after circulatory death liver transplantation in a controlled withdrawal protocol progrankme[J].Br J Surg, 2014, 101 (7) :784-792.
  • 加载中
计量
  • 文章访问数:  1648
  • HTML全文浏览量:  40
  • PDF下载量:  513
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-12-25
  • 出版日期:  2018-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回